pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
124
stories
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
Aug 28, 26
CAR T for autoimmune disease benefits from oncology’s lessons—and will deliver its own
biospace
Aug 27, 26
CAR Ts will only treat autoimmune diseases if we can scale delivery
biospace
Aug 26, 26
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
biospace
Aug 18, 26
Exclusive: Third death revealed in China's popular but opaque trials
endpoints
Aug 17, 26
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
Aug 14, 26
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
Aug 12, 26
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
Aug 12, 26
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
stat
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 31, 26
Syphilis spreads while researchers contend with federal constraints and a drug shortage
stat
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
Jul 30, 26
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
Jul 30, 26
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpoints
Jul 30, 26
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
Jul 29, 26
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
Jul 27, 26
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
Jul 27, 26
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
Jul 24, 26
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 17, 26
India’s life sciences sector at turning point for innovation: Report
biospace
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 8, 26
Bryan Johnson’s chronic disease is notoriously difficult to diagnose
stat
Jul 8, 26
Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
stat
Jun 7, 26
STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
stat
← prev
page 3 of 5
next →
